Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

8 Aug 2012

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in DNA repair. PARP inhibitors can act as chemosensitizers, or operate on the principle of synthetic lethality when used as single agent. Clinical trials have shown drugs in this class to be promising for BRCA mutation carriers. We postulated that inability to demonstrate response in non-BRCA carriers in which BRCA is inactivated by other mechanisms or with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22875744
DOI: 10.1007/s10549-012-2188-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibPMID 22875744Read ↗

Machine learning-based prediction of response to PARP inhibition across cancer typesSemantic proximity Read ↗

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell LinesSemantic proximity Read ↗

Signaling pathway evaluation of leading ATRi, PARPi and CDK7i cancer compounds targeting the DNA Damage Response using Causal InferenceSemantic proximity Read ↗

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor SensitivitySemantic proximity Read ↗

Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibitionSemantic proximity Read ↗

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.Semantic proximity Read ↗

Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast CancerSemantic proximity Read ↗

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor ResistanceSemantic proximity Read ↗

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancerSemantic proximity Read ↗

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancerSemantic proximity Read ↗

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired ResistanceSemantic proximity Read ↗

A quantitative chemotherapy genetic interaction map reveals new factors associated with PARP inhibitor resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.